A Structure-Based Approach for Mapping Adverse Drug Reactions to the Perturbation of Underlying Biological Pathways
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Adverse drug reactions (ADR), also known as side-effects, are complex undesired physiologic phenomena observed secondary to the administration of pharmaceuticals. Several phenomena underlie the emergence of each ADR; however, a dominant factor is the drug's ability to modulate one or more biological pathways. Understanding the biological processes behind the occurrence of ADRs would lead to the development of safer and more effective drugs. At present, no method exists to discover these ADR-pathway associations. In this paper we introduce a computational framework for identifying a subset of these associations based on the assumption that drugs capable of modulating the same pathway may induce similar ADRs. Our model exploits multiple information resources. First, we utilize a publicly available dataset pairing drugs with their observed ADRs. Second, we identify putative protein targets for each drug using the protein structure database and in-silico virtual docking. Third, we label each protein target with its known involvement in one or more biological pathways. Finally, the relationships among these information sources are mined using multiple stages of logistic-regression while controlling for over-fitting and multiple-hypothesis testing. As proof-of-concept, we examined a dataset of 506 ADRs, 730 drugs, and 830 human protein targets. Our method yielded 185 ADR-pathway associations of which 45 were selected to undergo a manual literature review. We found 32 associations to be supported by the scientific literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 1×
“Parkinson's disease (PD) is a progressive neurological disorder characterized by a large number of motor and non-motor features”
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Integration of biological networks and gene expression data using Cytoscape
Cline, M. S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., Christmas, R., Avila-Campilo, I., Creech, M., Gross, B., et al. (2007) · Nature Protocols · doi:10.1038/nprot.2007.324 · Cited by 2,507
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322 · cited 1×
“, (ii) the KEGG database of biological pathway annotation”
BackgroundPractice guidelines in acute pancreatitis
Banks, P. A., Freeman, M. L., & the Practice Parameters Committee of the American College of Gastroenterology (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00856.x · Cited by 2,050 · cited 1×
“. Elevated serum amylase level is one of the indicators of acute pancreatitis”
BackgroundBLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences
Tatusova, T. A., & Madden, T. L. (1999) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1999.tb13575.x · Cited by 1,789
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Benchmarking sets for molecular docking.
Huang, N., Shoichet, B. K., & Irwin, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0608356 · Cited by 1,318 · cited 1×
“). The theoretical probability of observing such an event (drawing 7 or more numbers greater than 1 from a normal distribution in 16 trials) is less than 0.0016. As a second test, we used the DUD benchmark”
MethodInfluentialDrug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 1×
“. Their findings reinforce the hypothesis that structurally similar drugs are likely to induce similar side-effects. Campillos et al. identified alternative targets for known drugs under the hypothesis that structurally similar drugs sharing similar side-effect profiles were also likely to share targets”
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
A side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899
Genome-wide association analysis by lasso penalized logistic regression
Wu, T. T., Chen, Y. F., Hastie, T., Sobel, E., & Lange, K. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp041 · Cited by 785 · cited 1×
“. Our computational model learns a set of connections from ADRs to pathways consistent with the observed drug-ADR relations. We note that for some drugs, the ADRs listed in the SIDER database are not traditional ADRs. For example, viral and bacterial infections, such as herpes and tuberculosis, are listed as ADRs but…”
MethodOff-Target Effects of Psychoactive Drugs Revealed by Genome-Wide Assays in Yeast
Ericson, E., Gebbia, M., Heisler, L. E., Wildenhain, J., Tyers, M., Giaever, G., & Nislow, C. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000151 · Cited by 89
Cited by
Open Babel: An open chemical toolbox
O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-33 · Cited by 10,939
Systematic Drug Repositioning Based on Clinical Side-Effects
Yang, L., & Agarwal, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028025 · Cited by 266
Drug repositioning for orphan diseases
Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228
In silico assessment of adverse drug reactions and associated mechanisms
Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.018 · Cited by 49
Fusion of nonclinical and clinical data to predict human drug safety
Johnson, D. E. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.3 · Cited by 9
Metadata
- Authors
- Wallach, I., Jaitly, N., & Lilien, R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-08-23
- Volume
- 5
- Issue
- 8
- Pages
- e12063
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1982438076
- Cited by
- 53
- References
- 15
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.